Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Innovation and openness, integration and win-win: Zhong Nanshan Guangzhou Laboratory signs a cooperation agreement on anti-epidemic drugs with six pharmaceutical companies including Zhongtian Shanghai and Lizhu Pharmaceutical

Published Time:

2022-06-13

On the morning of June 10, the 14th China Bioindustry Convention opened on Guangzhou International Bio Island. At the high-level forum, Zhong Nanshan, chairman of the conference, recipient of the "Medal of the Republic," and academician of the Chinese Academy of Engineering, delivered a keynote speech entitled "Technological Fight Against the Epidemic—Preventing the Epidemic, Stabilizing the Economy," exploring hot issues and development trends in global public health, human health, and strengthening the national biosafety risk prevention and control and governance system. Academician Zhong also reviewed the representative COVID-19 vaccines and therapeutic drugs currently in China that participated in the cooperative signing ceremony.

 

 Picture

 

Academician Zhong mentioned that the currently developed representative COVID-19 therapeutic drugs in China mainly include: 3CLpro inhibitors, siRNA, single herbal medicines, and antibody therapies. The Guangzhou Laboratory, which he leads, currently has five COVID-19 drug development projects underway, including many high-quality varieties jointly developed with other institutions, and the research and development progress is also among the industry leaders. Academician Zhong also made fair comments on the scientific research progress of some well-known research institutions and enterprises in China.

 

 Picture

 

Part 1

Progress in 3CL pro target development

3CLpro is an enzyme necessary for coronavirus replication and can serve as an effective antiviral drug target. Pfizer's PAXLOVID, which is currently on the market, also targets the same target. According to the PharmaXChange database, there are currently more than 40 pipeline drugs targeting this target globally, and many Chinese companies and research institutions are also involved. After the outbreak of the COVID-19 epidemic, the team of Academician Rao Zihe/Professor Yang Haitao responded quickly, resolving the high-resolution crystal structure of the 3CL hydrolase in just one week, and cooperating with Academician Jiang Hualiang's team to establish the potential drug N3. Zhensheng Rui Chuang's RAY1216 is currently in Phase I clinical trials. The Peng Wei team at the Guangzhou Laboratory is also attempting to develop the COVID-19 drug ICPR068 using structural biology and AI methods.

 

 Picture

 Picture

Part 2

Development of siRNA COVID-19 drugs

Academician Zhong Nanshan gave a special introduction to SNS812, developed in cooperation with Zhongtian Biology (National Taiwan University). As a representative drug of cross-strait cooperation and new mechanisms, SNS812, a small nucleic acid drug, has shown great potential in the field of COVID-19. As an inhalable small nucleic acid drug, SNS812 covers 99.8% of current COVID-19 virus variants. Tests show that SNS812 effectively inhibits major variants including the original strain and Alpha, Delta, Gamma, Epsilon, and Omicron, with an IC50 reaching the picomolar (pico-molar) level. Furthermore, in experiments with K18-hACE2 transgenic mice, prophylactic administration of SNS812 completely inhibited the production of live virus in the mouse lungs, and therapeutic administration also reduced the amount of live virus in the lungs by 96.2%, while avoiding lung alveolar damage, pulmonary thromboembolism, and lung immune cell infiltration caused by COVID-19. These data show that SNS812 is a drug with both therapeutic and preventive effects, and is not afraid of virus mutations. It has the potential to combat the rapid evolution and influenza-like nature of the COVID-19 virus and is a very promising treatment. The plan is to submit an IND and conduct Phase 1 clinical trials in China and the US in the second half of this year.

 

 Picture

 Picture

 Picture

 Picture

 

Part 3

Antibody types

The combination therapy of anbody and romisivirumab from Tenseng Biopharma is the first domestically approved COVID-19 neutralizing antibody. Phase III clinical studies have shown that in outpatients with high risk of disease progression, this combination therapy can reduce the composite endpoint of hospitalization and death by 80%. Innovent Biologics' COVID-19 neutralizing antibody IBI314 is undergoing Phase I/II clinical trials domestically and internationally.

 

 Picture

 Picture

 

Part 4

Innovative Traditional Chinese Medicine Forsythoside KD-1

As a representative of 1.1 innovative traditional Chinese medicine, it has now entered Phase II clinical trials and obtained results from 70 people.

 

 Picture

 

After the meeting, the Guangzhou Laboratory signed cooperation agreements with six pharmaceutical companies: Zhongtian (Shanghai), Lizhu Bio, Green Leaf Life, Poinsettia, Xiangxue Pharmaceutical, and Insilico Medicine, aiming to further enrich the Guangzhou Laboratory's pipeline. This cooperation will also have a demonstration effect on the collaborative efforts of China in the combination of production, education, and research, and in major scientific research projects.

 

 Picture